Format

Send to

Choose Destination
Blood. 2019 May 2;133(18):1922-1924. doi: 10.1182/blood-2019-03-901082.

Venetoclax: R-CHOP rocket booster?

Author information

1
Dana-Farber Cancer Institute.

Conflict of interest statement

Conflict-of-interest disclosure: C.H. received consulting fees from Gilead, Janssen, AbbVie, Roche, Genentech, and BMS. M.S.D. received consulting fees from AbbVie, Acerta Pharma, Adaptive Biotechnologies, Astra-Zeneca, Celgene, Genentech, Gilead Sciences, Janssen, MEI Pharma, Merck, Pharmacyclics, Roche, Syros Pharmaceuticals, TG Therapeutics, and Verastem; received research funding from Acerta Pharma, Bristol-Myers Squibb, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem; and received honoraria from Research to Practice. M.S.D. declares no competing financial interests.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center